Rachel L. Rosen

Rachel L. Rosen

Auto-generated profile, based on publicly available information

Rachel L. Rosen

Massachusetts General Hospital 2 Health Promotion and Resiliency Intervention Research Center Boston, Massachusetts

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 April 2019 in Nicotine & Tobacco Research
Verified
Journal Article
Closed access
PDF file
RRRachel L Rosen
Rachel L Rosen
MSMarc L Steinberg
Marc L Steinberg
The current literature on electronic cigarettes (e-cigarettes) thus far has focused on their harm reduction potential,1 use as a combustible cigarette cessation aid,2 toxicology profile,3 and concerns regarding uptake among youth.4 When e-cigarettes are used as a cessation aid, they are generally used for longer than the timeframe recommended for cessation aids approved by the US Food and Drug Administration (FDA), such as nicotine replacement therapies, bupropion, or varenicline.5

8 October 2021 in Nicotine & Tobacco Research
Verified
Journal Article
Open access
PDF file
AWAndrea H Weinberger
Andrea H Weinberger
MSMarc L Steinberg
Marc L Steinberg
SMSarah D. Mills
Sarah D. Mills
SDSarah S Dermody
Sarah S Dermody
JHJaimee L Heffner
Jaimee L Heffner
RRRachel L Rosen
Rachel L Rosen
This paper reports on topics discussed at a Society for Research on Nicotine and Tobacco pre-conference workshop at the 2019 annual Society for Research on Nicotine and Tobacco meeting. The goal of the pre-conference workshop was to help develop a shared understanding of the importance of several tobacco-related priority groups in tobacco use disorder (TUD) treatment research and to highlight challenges in measurement related to these groups. The workshop focused on persons with minoritized sex, gender identity, and sexual orientation identities; persons with minoritized racial and ethnic backgrounds; persons with lower socioeconomic status (SES); and persons with mental health concerns. In addition to experiencing commercial tobacco-related health disparities, these groups are also underrepresented in tobacco research, including TUD treatment studies. Importantly, there is wide variation in how and whether researchers are identifying variation within these priority groups. Best practices for measuring and reporting sex, gender identity, sexual orientation, race, ethnicity, SES, and mental health concerns in TUD treatment research are needed. This paper provides information about measurement challenges when including these groups in TUD treatment research and specific recommendations about how to measure these groups and assess potential disparities in outcomes. The goal of this paper is to encourage TUD treatment researchers to use measurement best practices in these priority groups in an effort to conduct meaningful and equity-promoting research. Increasing the inclusion and visibility of these groups in TUD treatment research will help to move the field forward in decreasing tobacco-related health disparities. Implications: Tobacco-related disparities exist for a number of priority groups including, among others, women, individuals with minoritized sexual and gender identities, individuals with minoritized racial and ethnic backgrounds, individuals with lower SES, and individuals with mental health concerns. Research on TUD treatments for many of these subgroups is lacking. Accurate assessment and consideration of these subgroups will provide needed information about efficacious and effective TUD treatments, about potential mediators and moderators, and for accurately describing study samples, all critical elements for reducing tobacco-related disparities, and improving diversity, equity, and inclusion in TUD treatment research.

12 March 2020 in Nicotine & Tobacco Research
Verified
Journal Article
Closed access
PDF file
MSMarc L Steinberg
Marc L Steinberg
RRRachel L Rosen
Rachel L Rosen
MVMark V Versella
Mark V Versella
ABAllison Borges
Allison Borges
TLTeresa M Leyro
Teresa M Leyro
Cigarette smoking disproportionately affects communities of low socioeconomic status where greater smoking prevalence and poorer cessation rates have been observed. Utilizing brief evidence-based interventions to increase cessation attempts may be an effective and easily disseminable means by which to mitigate undue burden in this population. The current intervention randomized daily smokers (N = 57) recruited from a local community soup kitchen to receive either Brief (eg, 30 m) Motivational Interviewing, Nicotine Replacement Therapy (NRT) sampling, or a Referral-Only intervention. Approximately half of participants (50.9%) reported not completing high school and many reported either just (41.4%) or not (40.4%) meeting basic expenses. Follow-up was completed approximately 1-month postintervention. Nonsignificant group differences indicated that participants randomized to the NRT sampling condition were more likely to make a quit attempt (moderate effect size). Approximately 40% of the sample reported making a serious quit attempt at follow-up. Significant differences in cigarettes per day at follow-up, controlling for baseline, were observed, with participants in the Motivational Interviewing condition, only, reporting significant reductions. Participants randomized to the NRT condition were significantly more likely to report using NRT patch and lozenge at follow-up (large effect). There were no differences between groups with respect to seeking behavioral support. Finally, we found that subjective financial strain moderated the effect of condition on change in cigarette consumption where NRT sampling was more effective for participants reporting less financial strain. Findings provide initial evidence for personalizing brief interventions to promote quit attempts in low-income smokers. While most clinical research on tobacco use and dependence focuses on successful sustained abstinence, the current study is novel because it examined three brief interventions designed to increase the number of quit attempts made by a nontreatment-seeking group suffering from health disparities (ie, smokers from socioeconomic disadvantage). These data suggest that nontreatment-seeking smokers from socioeconomic disadvantage can be influenced by Brief MIs and these interventions should be used to motivate smokers from socioeconomic disadvantage to make a quit attempt. Future studies should examine combined MIs including pharmacological and behavioral interventions.

28 November 2022 in Psychiatry Research
Verified
Journal Article
Closed access
RRRachel L. Rosen
Rachel L. Rosen
RRRahul S. Ramasubramani
Rahul S. Ramasubramani
NBNeal L. Benowitz
Neal L. Benowitz
KGKunal K. Gandhi
Kunal K. Gandhi
JWJill M. Williams
Jill M. Williams


6 July 2023 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Closed access
PDF file
JSJoanna Streck
Joanna Streck
JLJu-Whei Lee
Ju-Whei Lee
AWAngela Walter
Angela Walter
RRRachel L. Rosen
Rachel L. Rosen
IGIlana F. Gareen
Ilana F. Gareen
JOJamie S. Ostroff
Jamie S. Ostroff
Background: While cigarette smoking has declined among the U.S. general population, sale and use of non-cigarette alternative tobacco products (ATP; e.g., e-cigarettes, cigars) and dual use of cigarettes/ATPs are rising. Little is known about ATP use patterns in cancer survivors enrolled in clinical trials. We investigated prevalence of tobacco product use, and factors associated with past 30-day use, among patients with cancer in national trials. Methods: Cancer survivors (N = 756) enrolled in 9 ECOG-ACRIN clinical trials (2017–2021) completed a modified Cancer Patient Tobacco Use Questionnaire (C-TUQ) which assessed baseline cigarette and ATP use since cancer diagnosis and in the past 30 days. Results: Patients were on average 59 years old, 70% male, and the mean time since cancer diagnosis was 26 months. Since diagnosis, cigarettes (21%) were the most common tobacco product used, followed by smokeless tobacco use (5%), cigars (4%), and e-cigarettes (2%). In the past 30 days, 12% of patients reported smoking cigarettes, 4% cigars, 4% using smokeless tobacco, and 2% e-cigarettes. Since cancer diagnosis, 5.5% of the sample reported multiple tobacco product use, and 3.0% reported multiple product use in the past 30 days. Males (vs. females; OR 4.33; P = 0 < 0.01) and individuals not living with another person who smokes (vs. living with; OR, 8.07; P = 0 < 0.01) were more likely to use ATPs only versus cigarettes only in the past 30 days. Conclusions: Among patients with cancer, cigarettes were the most prevalent tobacco product reported. Impact: Regardless, ATPs and multiple tobacco product use should be routinely assessed in cancer care settings.